Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Other

AACR 2026: Revolution’s next prospect, Merck’s reveal and a lung cancer battle

 April 20, 2026

BioPharma Dive

Featured at this year s meeting on early cancer research were results from an immunotherapy Merck acquired in 2024 and several targeted medicines for lung tumors.

OtherOncologyRead full story

Post navigation

Boehringer Ingelheim launches AI centre in London →
← 221: An Interview With Dutch Neurologist Ewout Groen of SMA Europe

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com